Skip to main content
NCBI home page
Cellular & Molecular Biology Letters logoLink to Cellular & Molecular Biology Letters
. 2006 Sep 1;11(3):360. doi: 10.2478/s11658-006-0030-6

A comparison of the in vitro antimicrobial activity of liposomes containing meropenem and gentamicin

Zuzanna Drulis-Kawa 1,3,✉, Jerzy Gubernator 2,4, Agata Dorotkiewicz-Jach 1, Włodzimierz Doroszkiewicz 1, Arkadiusz Kozubek 2
PMCID: PMC6472838  PMID: 16847556

Abstract

The antimicrobial activity of eight cationic, two neutral and three anionic liposome compositions containing meropenem and gentamicin was tested in vitro in broth and serum medium. The cationic formulations showed better antibacterial efficacy against both Gram-positive and Gram-negative bacteria than the anionic and neutral ones, regardless of the encapsulated drug. The most effective formulations were the cationic PC/DOPE/DOTAP 3:4:3 and PC/Chol/DOTAP 3:4:3, as the MICs with meropenem were 2 to 4 times lower than those of the free drug.

Key words: Liposomes, Meropenem, Gentamicin, Bacteria

Full Text

The Full Text of this article is available as a PDF (457.5 KB).

Abbreviations used

Chol

cholesterol

DDAB

dimethyldioctadecylammoniumbromide salt

DMPG

1,2-dimyristoyl-sn-glycero-3-phosphoglycerol

DOPE

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine

DOTAP

1,2-dioleoyloxy-3-trimethyl ammonium-propane

DPPC

1,2-diplamitoyl-sn-glycero-3-phosphocholine

GE

gentamicin

MEM

meropenem

MHB

Mueller Hinton II Broth

MLVs

the multilamellar vesicles

MIC

minimum inhibitory concentration

MPS

the mononuclear phagocytic system

NBS

normal bovine serum

NCCLS

National Committee for Clinical Laboratory Standards

OPA

o-phthaldialdehyde

PBS

phosphate-buffered solution

PC

phosphatidylcholine

PI

phosphatidyl inositiol

SA

octadecylamine

ULVs

unilamellar vesicles

References

  • 1.Mayer L.D., Bally M.B., Loughrey H., Masin D., Cullis P.R. Liposomal vincistine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res. 1990;50:575–579. [PubMed] [Google Scholar]
  • 2.Mayer L.D., Bally M.B., Cullis P.R., Wilson S.L., Emerman J.T. Comparison of free and liposome encapsulated doxorubicin tumor uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett. 1990;53:183–190. doi: 10.1016/0304-3835(90)90212-G. [DOI] [PubMed] [Google Scholar]
  • 3.De Marie S., Janknegt R., Bakker-Woudenberg I.A.J.M. Clinical use of liposomal and lipid complexes amphotericin B. J. Antimicrob. Chemother. 1994;33:907–916. doi: 10.1093/jac/33.5.907. [DOI] [PubMed] [Google Scholar]
  • 4.Patterson T.F., Andrioli V.T. The role of liposomal amphotericin B in the treatment of systemic fungal infections. Eur. J. Cancer Oncol. 1989;25:63–68. [PubMed] [Google Scholar]
  • 5.Bakker-Woudenberg I.A.J.M. Delivery of antimicrobials to infected tissue macrophages. Adv. Drug Deliv. Rev. 1995;17:5–20. doi: 10.1016/0169-409X(95)00037-8. [DOI] [Google Scholar]
  • 6.Pinto-Alphandary H., Andremont A., Couvreur P. Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. Int. J. Antimicrob. Agents. 2000;13:155–168. doi: 10.1016/S0924-8579(99)00121-1. [DOI] [PubMed] [Google Scholar]
  • 7.Omri A., Suntres Z.E., Shek P.N. Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection. Biochem. Pharmacol. 2002;64:1407–1413. doi: 10.1016/S0006-2952(02)01346-1. [DOI] [PubMed] [Google Scholar]
  • 8.Sachetelli S., Beaulac C., Riffon R., Lagace J. Evaluation of the pulmonary and systemic immunogenicity of Fluidosomes, a fluid liposomaltobramycin formulation for the treatment of chronic infections in lungs. Biochim. Biophys. Acta. 1999;1428:334–340. doi: 10.1016/s0304-4165(99)00078-1. [DOI] [PubMed] [Google Scholar]
  • 9.Schiffelers R., Storm G., Bakker-Woudenberg I.A.J.M. Host factors influencing the preferential localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue. Pharmaceutic. Res. 2001;18:780–787. doi: 10.1023/A:1011080211226. [DOI] [PubMed] [Google Scholar]
  • 10.Schiffelers R., Storm G., Bakker-Woudenberg I.A.J.M. Liposomeencapsulated aminoglycosides in pre-clinical and clinical studies. J. Antimicrob. Chemother. 2001;48:333–344. doi: 10.1093/jac/48.3.333. [DOI] [PubMed] [Google Scholar]
  • 11.Webb M.S., Boman N.L., Wiseman D.J., Saxon D., Sutton K., Wong K.F., Logan P., Hope M.J. Antibacterial efficacy against an in vivo Salmonella typhimurium infection model and pharmacokinetics of a liposomal ciprofloxacin formulation. Antimicrob. Agents Chemother. 1998;42:45–52. doi: 10.1128/aac.42.1.45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Beaulac C., Clement-Major S., Hawari J., Lagace J. Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection. Antimicrob. Agents Chemother. 1996;40:665–669. doi: 10.1128/aac.40.3.665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Schiffelers R., Storm G., Ten Kate M.T., Bakker-Woudenberg I.A.J.M. Therapeutic efficacy of liposome-encapsulated gentamicin in rat Klebsiella pneumoniae pneumonia in relation to impaired host defence and low bacterial susceptibility to gentamicin. Antimicrob. Agents Chemother. 2001;45:464–470. doi: 10.1128/AAC.45.2.464-470.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Desai T.R., Tyrrell G.J., Ng T., Finlay W.H. In vitro evaluation of nebulization properties, antimicrobial activity, and regional airway surface liquid concentration of liposomal polymyxin B sulfate. Pharmaceutic. Res. 2003;20:442–447. doi: 10.1023/A:1022664406840. [DOI] [PubMed] [Google Scholar]
  • 15.Deol P., Khuller G.K. Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim. Biophys. Acta. 1997;1334:161–172. doi: 10.1016/s0304-4165(96)00088-8. [DOI] [PubMed] [Google Scholar]
  • 16.Labana S., Pandey R., Sharma S., Khuller G.K. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes. Int. J. Antimicrob. Agents. 2002;20:301–304. doi: 10.1016/S0924-8579(02)00175-9. [DOI] [PubMed] [Google Scholar]
  • 17.Mehta R.T., Keyhani A., McQueen T.J., Rosenbaum B., Rolston K.V., Tarrand J.J. In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and M. tuberculosis. Antimicrob. Agents Chemother. 1993;37:2584–2587. doi: 10.1128/aac.37.12.2584. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Duzgunes N., Flasher D., Venkata Reddy M., Luna-Herrera J., Pattisapu R., Gangadharam J. Treatment of intracellular Mycobacterium avium complex infection by free and liposome-encapsulated sparfloxacin. Antimicrob. Agents Chemother. 1996;40:2618–2621. doi: 10.1128/aac.40.11.2618. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Cordeiro C., Wiseman D.J., Lutwyche P., Uh M., Evans J.C., Finlay B.B., Webb M.S. Antibacterial efficacy of gentamicin encapsulated in pH-sensitive liposomes against an in vivo Salmonella enterica serovar Typhimurium intracellular infection model. Antimicrob. Agents Chemother. 2000;44:533–539. doi: 10.1128/AAC.44.3.533-539.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Lutwyche P., Cordeiro C., Wiseman D.J., St-Louis M., Uh M., Hope M.J., Webb M.S., Finlay B.B. Intracellular delivery and antibacterial activity of gentamicin encapsulated in pH-sensitive liposomes. Antimicrob Agents Chemother. 1998;42:2511–2520. doi: 10.1128/aac.42.10.2511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Magallanes M., Dijkstra J., Fierer J. Liposome-incorporated ciprofloxacin in the treatment of murine salmonellosis. Antimicrob. Agents Chemother. 1993;37:2293–2297. doi: 10.1128/aac.37.11.2293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Wong J.P., Yang H., Blasetti K.L., Schnell G., Conley J., Schofield L.N. Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection. J. Control. Release. 2003;92:265–273. doi: 10.1016/S0168-3659(03)00358-4. [DOI] [PubMed] [Google Scholar]
  • 23.Bakker-Woudenberg I.A.J.M., Lokerse A.F., Roerdink F.H., Regts D., Michel M.F. Free versus liposome-entrapped ampicillin in treatment of infection due to Listeria monocytogenes in normal and athymic (nude) mice. J. Infect. Dis. 1985;151:917–924. doi: 10.1093/infdis/151.5.917. [DOI] [PubMed] [Google Scholar]
  • 24.Sanderson N.M., Jones M.N. Interaction of cationic liposomes with skin bacteria. Biochem Soc. Trans. 1995;23:561S. doi: 10.1042/bst023561s. [DOI] [PubMed] [Google Scholar]
  • 25.Sanderson N.M., Guo B., Jacob A.E., Handley P.S., Cunniffe J.G., Jones M.N. The interaction of cationic liposomes with the skin-associated bacterium Staphylococcus epidermidis: effects of ionic strength and temperature. Biochim. Biophys. Acta. 1996;1283:207–214. doi: 10.1016/0005-2736(96)00099-5. [DOI] [PubMed] [Google Scholar]
  • 26.Jones M.N., Francis S.E., Hutchinson F.J., Lyle I.G. Targeting and delivery of bactericide to adsorbed oral bacteria by use of proteoliposomes. Biochim Biophys. Acta. 1993;1147:251–261. doi: 10.1016/0005-2736(93)90010-W. [DOI] [PubMed] [Google Scholar]
  • 27.Beaulac C., Clement-Major S., Hawari J., Lagace J. In vitro kinetics of drug release and pulmonary retention of microencapsulated antibiotic in liposomal formulations in relation to the lipid composition. J. Microencapsul. 1997;14:335–348. doi: 10.3109/02652049709051137. [DOI] [PubMed] [Google Scholar]
  • 28.Beaulac C., Sachetelli S., Lagace J. In vitro bactericidal efficacy of sub-MIC concentrations of liposome-encapsulated antibiotic against Gramnegative and Gram-positive bacteria. J. Antimicrob. Chemother. 1998;41:35–41. doi: 10.1093/jac/41.1.35. [DOI] [PubMed] [Google Scholar]
  • 29.Furneri P.M., Fresta M., Puglisi G., Tempera G. Ofloxacin-loaded liposomes: in vitro activity and drug accumulation in bacteria. Antimicrob. Agents Chemother. 2000;44:2458–2464. doi: 10.1128/AAC.44.9.2458-2464.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Omri A., Ravaoarinoro M. Preparation, properties and the effects of amikacin, netilmicin and tobramycin in free and liposomal formulations on Gram-negative and Gram-positive bacteria. Int. J. Antimicrob. Agents. 1996;7:9–14. doi: 10.1016/0924-8579(96)00003-9. [DOI] [PubMed] [Google Scholar]
  • 31.Puglisi G., Fresta M., Mazzone G., Furneri P.M., Tempera G. Formulation parameters of fluoroquinolone-loaded liposomes and in vitro antimicrobial activity. Int. J. Pharm. 1995;118:65–76. doi: 10.1016/0378-5173(94)00340-B. [DOI] [Google Scholar]
  • 32.Sachetelli S., Khalil H., Chen T., Beaulac C., Senechal S., Lagace J. Demonstration of a fusion mechanism between a fluid bactericidal liposomal formulation and bacterial cells. Biochim. Biophys. Acta. 2000;1463:254–266. doi: 10.1016/S0005-2736(99)00217-5. [DOI] [PubMed] [Google Scholar]
  • 33.Stewart J.C. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal. Biochem. 1980;104:10–14. doi: 10.1016/0003-2697(80)90269-9. [DOI] [PubMed] [Google Scholar]
  • 34.Dreetz M., Hamacher J., Eller J., Bomer K., Koeppe P., Schaberg T., Lode H. Serum bactericidal activities and comparative phamakokinetics of meropenem and imipenem-cilastatin. Antimicrob. Agents Chemother. 1996;40:105–109. doi: 10.1128/aac.40.1.105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Fifth Edition. Villanova, Pa, USA: NCCLS; 2000. [Google Scholar]
  • 36.Gregoriadis G. Fate of injected liposomes: observations on entrapped solute retention vesicle clearance and tissue distribution in vivo. In: Gregoriadis G., editor. Liposomes as Drug Carriers, Recent Trends and Progress. Chichester: John Wiley and Sons; 1988. pp. 3–18. [Google Scholar]
  • 37.Krieger, J., Childs, S. and Klimberg, I. UTI treatment using liposomal amikacin (MiKasone®). In Program and Abstracts of the Ninth European Congress of Clinical Microbiology and Infectious Diseases, Berlin, 1999. Clinical Microbiology and Infection 5S3, 1999, Abstract P194.
  • 38.Hernandez-Caselles T., Vera A., Crespo F., Villalain J., Gomez-Fernandez J. C. Treatment of Brucella melitensis infection in mice by use of liposome-encapsulated gentamicin. Am. J. Vet. Res. 1989;50:1486–1488. [PubMed] [Google Scholar]
  • 39.Vitas A.I., Diaz R., Gamazo C. Protective effect of liposomal gentamicin against systemic acute murine brucellosis. Chemotherapy. 1997;43:204–210. doi: 10.1159/000239563. [DOI] [PubMed] [Google Scholar]
  • 40.Swenson C.E., Popescu M.C., Ginsberg R.S. Preparation and use of liposomes in the treatment of microbial infections. Crit. Rev. Microbiol. 1988;15:1–31. doi: 10.3109/10408418809104463. [DOI] [PubMed] [Google Scholar]
  • 41.Drulis-Kawa Z., Gubemator J., Kostyn K., Doroszkiewicz W., Kozubek A. Liposome-encapsulated carbapenems. Cell. Mol. Biol. Lett. 2002;7:281. [PubMed] [Google Scholar]
  • 42.Drulis-Kawa Z., Gubernator J., Dorotkiewicz-Jach A., Doroszkiewicz W., Kozubek A. In vitro antimicrobial activity of liposomal meropenem against Pseudomonas aeruginosa strains. Int. J. Pharm. 2006;315:59–66. doi: 10.1016/j.ijpharm.2006.02.017. [DOI] [PubMed] [Google Scholar]
  • 43.Sihorkar V., Vyas S.P. Biofilm consortia on biomedical and biological surfaces: delivery and targeting strategies. Pharmaceutic. Res. 2001;18:1247–1254. doi: 10.1023/A:1013073508318. [DOI] [PubMed] [Google Scholar]

Articles from Cellular & Molecular Biology Letters are provided here courtesy of BMC

RESOURCES